• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific takes to the airwaves with Watchman TV ads

Boston Scientific takes to the airwaves with Watchman TV ads

July 11, 2017 By Fink Densford

Boston Scientific

Boston Scientific (NYSE:BSX) has taken to the airwaves, airing television commercials for its Watchman device in 4 US metro areas, according to a Boston Globe report.

The company aired commercials, aimed at families with older relatives with possible heart problems, in Tampa, Detroit, San Diego and Phoenix this spring, according to the report.

Direct to consumer marketing through television ads is rare for medical device companies, though commonplace for pharmaceutical manufacturers. Boston Scientific said the commercials are part of its strategy to promote its new products and pursue sector leadership in cardiac, endoscopic, urological and other devices, according to the report.

With the strategy, the company hopes to position itself with the major players in the industry as the industry consolidates and shrinks, the Boston Globe reports.

“Hospitals want to drive great outcomes, and they also want to save money. So what they’re typically doing is reducing down the number of suppliers that they work with. What’s most important to us is to have very differentiated products so that when Mass. General or whoever picks partners, we’re part of the answer,” CEO Mike Mahoney told the paper.

The decision to air the ads came with “a lot of hand-wringing,” according to chief medical officer Ian Meredith. But the company determined the ads would have a positive effect in educating patients with atrial fibrillation who are commonly on anti-coagulant blood thinners, according to the report.

“This is a very socially impactful ad. It’s really identifying that there’s an alternative for people who can’t take anti-coagulation or who are struggling with anti-coagulation [medicines]. And a lot of primary care doctors don’t realize this option’s available,” Meredith told the Boston Globe.

Boston Scientific said it is waiting to gauge the effectiveness of the existing ads before considering rollouts in other regions.

Last month, Boston Scientific revealed its plan to improve operating margins over the next few years, setting its sights on earnings growth of at least 10%.

Filed Under: Business/Financial News, Cardiovascular Tagged With: Boston Scientific

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy